Eligible, privately insured patients may pay as little as $10 per prescription, up to a maximum program savings of $300 per patient. Coupon may be redeemed before the expiration date printed on the coupon, on each qualifying prescription up to a 5-day supply.
Authorized for emergency use in the treatment of COVID-19
- LAGEVRIO™ (molnupiravir) has not been approved, but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA), for the treatment of adults with mild-to-moderate COVID-19, who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.
- The emergency use of LAGEVRIO is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (“the Act”), 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
Please see Authorized Use Statement and Important Safety Information continued below.
STEP 1: Select the appropriate option:
STEP 2: Review and accept the Terms and Conditions of the coupon:
- The coupon is valid on qualifying prescriptions for LAGEVRIO. Patient is responsible for the first $10 of out-of-pocket costs on each prescription, up to a maximum program savings of $300 per patient.
- Patient must have private insurance with coverage for LAGEVRIO in order to be eligible for the coupon.
- The coupon is valid for up to a 5-day supply. The coupon may be redeemed only once every 30 days.
- No other purchase is necessary.
- The coupon is not transferable. No substitutions are permitted. The offer cannot be combined with any other coupon, free trial, discount, prescription savings card, or other offer.
- The coupon is not insurance.
- Patient must have private insurance. Not valid for uninsured patients or patients covered under Medicaid (including Medicaid patients enrolled in a qualified health plan purchased through a health insurance exchange [marketplace] established by a state government or the federal government), Medicare, a Medicare Part D or Medicare Advantage plan (regardless of whether a specific prescription is covered), TRICARE, CHAMPUS, Puerto Rico Government Health Insurance Plan ("Healthcare Reform"), or any other state or federal medical or pharmaceutical benefit program or pharmaceutical assistance program (collectively, "Government Programs").
- Subject to changes in state law, the coupon may become invalid for residents of Massachusetts prior to its expiration date.
- You must be 18 years of age or older to redeem the coupon. Patient, pharmacist, and prescriber agree not to seek reimbursement for all or any part of the benefit received by the patient through the offer. Patient is responsible for reporting receipt of coupon benefit to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the coupon, as may be required.
- The coupon can be used only by eligible residents of the United States or the Commonwealth of Puerto Rico at participating eligible retail or mail-order pharmacies in the United States or the Commonwealth of Puerto Rico. Product must originate in the United States or the Commonwealth of Puerto Rico.
- The coupon is the property of Merck and must be turned in on request.
- It is illegal to sell, purchase, trade, or counterfeit, or offer to sell, purchase, trade, or counterfeit the coupon. Void if reproduced. Void where prohibited by law, taxed, or restricted.
- Merck reserves the right to rescind, revoke, or amend the offer at any time without notice.
- Data related to your redemption of the coupon may be collected, analyzed, and shared with Merck, for market research and other purposes related to assessing coupon programs. Data shared with Merck will be aggregated and de-identified, meaning it will be combined with data related to other coupon redemptions and will not identify you.
- Expiration Date: 2/28/25.
STEP 3: Answer the activation questions regarding eligibility. You may be required to enter prescription insurance information, so please have the insurance card ready. Not all patients are eligible. Please see the Terms and Conditions above.
STEP 4: Please note that the coupon is only available via email delivery. If you are eligible for the coupon, you will need to provide an email address to receive the coupon.
STEP 5: The activated coupon will be ready to use at an eligible pharmacy.
You must confirm that you have read and agree to the Terms and
Conditions of the coupon.
You must select an option in Step 1 to proceed.
Authorized Use:
-
LAGEVRIO™ (molnupiravir) is an investigational medicine used to treat adults with mild-to-moderate COVID-19:
- who are at risk for progression to severe COVID-19 including hospitalization or death, and for whom other COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.
-
LAGEVRIO is not authorized:
- For use in people less than 18 years of age
- For prevention of COVID-19
- For patients needing hospitalization for COVID-19
- For use for longer than 5 consecutive days
Important Safety Information
- LAGEVRIO may cause harm to your unborn baby. It is not known if LAGEVRIO will harm your baby if you take LAGEVRIO during pregnancy. LAGEVRIO is not recommended for use in pregnancy and has not been studied in pregnancy.
- You and your healthcare provider may decide that you should take LAGEVRIO during pregnancy if there are no other COVID-19 treatment options approved or authorized by the FDA that are accessible or clinically appropriate for you. If you and your healthcare provider decide that you should take LAGEVRIO during pregnancy, you and your healthcare provider should discuss the known and potential benefits and the potential risks of taking LAGEVRIO during pregnancy.
Please read Important Safety Information continued below.
Important Safety Information (continued)
- Individuals who are able to become pregnant should use a reliable method of birth control (contraception) correctly and consistently during treatment with LAGEVRIO and for 4 days after the last dose of LAGEVRIO. Talk to your healthcare provider about reliable birth control methods and tell your healthcare provider right away if you become pregnant or think you may have become pregnant during treatment with LAGEVRIO. Before starting treatment with LAGEVRIO your healthcare provider may do a pregnancy test to see if you are not pregnant.
- There is a pregnancy registry for individuals who take LAGEVRIO during pregnancy. The purpose of this program is to collect information about the health of you and your baby. If you are pregnant or become pregnant during treatment with LAGEVRIO, you are encouraged to report your use of LAGEVRIO during pregnancy to this pregnancy registry at https://covid-pr.pregistry.com or 1-800-616-3791.
- It is not known if LAGEVRIO can affect sperm, but the risk is regarded as low, based on animal studies. A reliable method of birth control (contraception) should be used correctly and consistently during treatment with LAGEVRIO and for at least 3 months after the last dose. The risk to sperm beyond 3 months is not known. Talk to your healthcare provider about reliable birth control methods or if you have questions or concerns about how LAGEVRIO may affect sperm.
- Before taking LAGEVRIO, tell your healthcare provider about all of your medical conditions including if you have any allergies, serious illnesses, or are pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed.
- Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
- Allergic reactions can happen in people taking LAGEVRIO even after only 1 dose. Stop taking LAGEVRIO and call your healthcare provider right away if you get any of the following symptoms of an allergic reaction: hives, rapid heartbeat, trouble swallowing or breathing, swelling of the mouth, lips, or face, throat tightness, hoarseness, or skin rash.
- The most common side effects of LAGEVRIO are diarrhea, nausea, and dizziness. These are not all the possible side effects of LAGEVRIO. Serious and unexpected side effects may happen. This medicine is still being studied, so it is possible that all of the risks are not known at this time. Contact your healthcare provider if you have any side effects that bother you or do not go away.
- Breastfeeding is not recommended during treatment with LAGEVRIO and for 4 days after the last dose of LAGEVRIO. If you are breastfeeding or plan to breastfeed, talk to your healthcare provider about your options and specific situation before taking LAGEVRIO.
- Take LAGEVRIO exactly as your healthcare provider tells you to take it. Take LAGEVRIO for 5 days. It is important that you complete the full 5 days of treatment with LAGEVRIO. Do not stop taking LAGEVRIO before you complete the full 5 days of treatment, even if you feel better.
-
Contact your healthcare provider if you have any side effects that bother you or do not go away. Report side effects to FDA MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).
Please read the accompanying Fact Sheet for Patients and Caregivers for LAGEVRIO™ (molnupiravir) and discuss it with your doctor. The Fact Sheet for Healthcare Providers also is available.